United States HR 8190: Biosimilar Insulin Access Act of 2020

Status: Sponsor introductory remarks on measure. (CR H4487) (as of 2020-09-16)

State: United States · Session: 116 · Bill: HR 8190

Subjects: Blood and blood diseases, Competition and antitrust, Drug safety, medical device, and laboratory regulation, Drug therapy, Health technology, devices, supplies, Intellectual property, Licensing and registrations, Prescription drugs

Sponsors: Glenn Grothman, Michael F. Q. San Nicolas

View United States HR 8190 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.